Business Description
Cadrenal Therapeutics Inc
NAICS : 541713
SIC : 2833
ISIN : US1276362076
Total Employee Number:
4Description
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.63 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 17.6 | |||||
9-Day RSI | 26.62 | |||||
14-Day RSI | 30.26 | |||||
3-1 Month Momentum % | -30.77 | |||||
6-1 Month Momentum % | -59.39 | |||||
12-1 Month Momentum % | -72.84 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.68 | |||||
Quick Ratio | 2.68 | |||||
Cash Ratio | 2.17 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -44.4 | |||||
Shareholder Yield % | -86.29 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -336.17 | |||||
ROA % | -235.82 | |||||
ROIC % | -2728.03 | |||||
ROC (Joel Greenblatt) % | -240940 | |||||
ROCE % | -340.66 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 3.26 | |||||
Price-to-Tangible-Book | 3.32 | |||||
EV-to-EBIT | -0.24 | |||||
EV-to-Forward-EBIT | -0.2 | |||||
EV-to-EBITDA | -0.24 | |||||
EV-to-Forward-EBITDA | -0.2 | |||||
EV-to-FCF | -0.27 | |||||
| Price-to-Net-Current-Asset-Value | 3.37 | |||||
| Price-to-Net-Cash | 4.78 | |||||
Earnings Yield (Greenblatt) % | -416.67 | |||||
FCF Yield % | -150.45 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CVKD
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cadrenal Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -5.63 | ||
| Beta | 1.7432 | ||
| 3-Year Sharpe Ratio | 0.01 | ||
| 3-Year Sortino Ratio | 0.02 | ||
| Volatility % | 85.34 | ||
| 14-Day RSI | 30.26 | ||
| 14-Day ATR ($) | 0.447241 | ||
| 20-Day SMA ($) | 3.0325 | ||
| 12-1 Month Momentum % | -72.84 | ||
| 52-Week Range ($) | 2.29 - 14.64 | ||
| Shares Outstanding (Mil) | 3.1 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cadrenal Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cadrenal Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-10 | In 117 days | ||
| General meeting for 2026 | 2026-09-24 10:00 | In 71 days | ||
| Second quarter earnings results for 2026 | 2026-08-11 | In 26 days | ||
| First quarter earnings results for 2026 | 2026-05-07 | 6.17 (-4.34%) | ||
| Annual report for 2025 | 2026-03-31 | 4.25 (-14.83%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-31 | 4.25 (-14.83%) | ||
| Third quarter earnings results for 2025 | 2025-11-10 | 12.15 (+0.04%) | ||
| General meeting for 2025 | 2025-09-24 10:00 | 13.68 (+4.03%) | ||
| Second quarter earnings results for 2025 | 2025-08-11 | 11.15 (+6.29%) | ||
| First quarter earnings results for 2025 | 2025-05-08 | 16.28 (+2.49%) |
Show
Entries
Cadrenal Therapeutics Inc Frequently Asked Questions
What is Cadrenal Therapeutics Inc(CVKD)'s stock price today?
The current price of CVKD is $2.39. The 52 week high of CVKD is $14.64 and 52 week low is $2.29.
When is next earnings date of Cadrenal Therapeutics Inc(CVKD)?
The next earnings date of Cadrenal Therapeutics Inc(CVKD) is 2026-08-11 Est..
Does Cadrenal Therapeutics Inc(CVKD) pay dividends? If so, how much?
Cadrenal Therapeutics Inc(CVKD) does not pay dividend.
Guru Commentaries on NAS:CVKD
No articles.
Press Release
Articles on Cadrenal Therapeutics Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers